Monte Rosa [GLUE] vs Regeneron [REGN] Detailed Stock Comparison

Monte Rosa Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Monte Rosa Therapeutics Inc. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 16 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Monte Rosa Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 49.22 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 5.67 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 16.82 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -0.12 -4.80 Monte Rosa Therapeutics Inc.
EV/EBITDA -27.83 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -31.23% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -1,787.67% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -16.94% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -7.64% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-27.50M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 371.53% 25.39% Monte Rosa Therapeutics Inc.
Price-to-Sales Ratio (TTM) 13.05 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $1.28B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 10.32 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $1 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-0.46 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.64 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 20.65% 2.55% Regeneron Pharmaceuticals, Inc.

Monte Rosa Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

GLUE
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Monte Rosa Therapeutics Inc.-0.85%-8.24%-10.12%-2.06%4.33%14.89%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Monte Rosa Therapeutics Inc.371.53%160.71%4.51%4.51%4.51%4.51%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Monte Rosa Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricGLUEREGN
Market Information
Market Cap i$1.61B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i947,771642,495
90 Day Avg. Volume i1,225,390617,765
Last Close$17.59$618.95
52 Week Range$4.12 - $25.77$476.49 - $821.11
% from 52W High-31.74%-24.62%
All-Time High$45.56 (Sep 06, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-61.39%-48.90%
Growth Metrics
Quarterly Revenue Growth-0.95%0.03%
Quarterly Earnings Growth-0.95%-0.08%
Financial Health
Profit Margin (TTM) i-0.31%0.31%
Operating Margin (TTM) i-17.88%0.23%
Return on Equity (TTM) i-0.17%0.15%
Debt to Equity (MRQ) i16.829.51
Cash & Liquidity
Book Value per Share (MRQ)$3.56$304.65
Cash per Share (MRQ)$4.71$83.86
Operating Cash Flow (TTM) i$-22,798,000$4.98B
Levered Free Cash Flow (TTM) i$-129,076,000$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Monte Rosa Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricGLUE (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i49.2218.00
Forward P/E i-11.8614.21
PEG Ratio i-0.12-4.80
Price to Sales (TTM) i13.055.50
Price to Book (MRQ) i5.672.45
Market Capitalization
Market Capitalization i$1.61B$80.98B
Enterprise Value i$1.28B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i10.324.95
Enterprise to EBITDA i-27.8316.72
Risk & Other Metrics
Beta i1.640.40
Book Value per Share (MRQ) i$3.56$304.65

Financial Statements Comparison: Monte Rosa Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLUE (2025)REGN (2025)
Revenue/Sales i123.67M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i141.50M5.85B
Operating Income (EBIT) i-54.21M3.70B
Operating Margin i-43.8%25.8%
EBITDA i-47.40M5.00B
EBITDA Margin i-38.3%34.8%
Pre-Tax Income i-39.72M5.23B
Pre-Tax Income % of Revenue i-32.1%36.5%
Income Tax i-1.10M725.80M
Income Tax % of Revenue i-0.9%5.1%
Net Income (Profit) i-38.63M4.50B
Profit Margin i-31.2%31.4%

Balance Sheet & Liquidity Metrics

MetricGLUE (2025)REGN (2025)
Cash & Equivalents i129.88M3.12B
Total Current Assets i393.19M18.02B
Total Current Assets % of Revenue i317.9%125.7%
Total Current Liabilities i64.21M4.37B
Total Current Liabilities % of Revenue i51.9%30.5%
Long-Term Debt i34.79M2.71B
Long-Term Debt % of Revenue i28.1%18.9%
Total Shareholders Equity i233.06M31.26B
Retained Earnings i-477.21M35.80B
Retained Earnings % of Revenue i-385.9%249.6%
Property, Plant & Equipment i51.41M1.54B

Cash Flow Statement Comparison

MetricGLUE (2025)REGN (2025)
Operating Cash Flow i-29.05M6.30B
Operating Cash Flow % of Revenue i-23.5%43.9%
Capital Expenditures i-4.70M0
Free Cash Flow i-27.50M3.77B
FCF Margin i-22.2%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase i-357,000-3.97B

Short Interest & Institutional Ownership Analysis

MetricGLUEREGN
Shares Short i13.40M2.55M
Short Ratio i10.824.46
Short % of Float i20.65%2.55%
Shares Outstanding i65.54M105.72M
Float Shares i57.20M98.55M
% Held by Insiders i0.74%1.98%
% Held by Institutions i87.50%91.08%
% Held by Public i11.76%6.94%

Dividend Analysis & Yield Comparison: Monte Rosa Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricGLUEREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026